# Auto Review: results.txt

Generated: 2026-04-28 16:49
Reviewer: Qwen2.5-32B-Instruct-AWQ (auto_review.py)

## Summary

- **Samples**: 30
- **Clean**: 0/30
- **P0** (hallucination): 0
- **P1** (major error): 32
- **P2** (minor issue): 113

### Critical Issues

- **ROW 6** [P1]: The note mentions 'lanreotide', not 'capecitabine'.
- **ROW 6** [P1]: The extracted data states 'Continue lanreotide 120 mg/mo', but the letter incorrectly mentions 'capecitabine'.
- **ROW 7** [P1]: Inaccurate staging information. The correct staging is pT3 N1, not Stage II-III.
- **ROW 14** [P1]: Inaccurate description of the tumor location. The tumor is of duodenal origin, not pancreatic.
- **ROW 15** [P1]: Incomplete sentence with missing critical information (specific medication name).
- **ROW 18** [P1]: The note states the patient originally had Stage IB pancreatic adenocarcinoma, and now has metastatic disease, but the extracted 'Stage IIB' is not supported.
- **ROW 18** [P1]: The lab results provided in the extracted data do not match the note, which does not contain specific lab values like WBC, Hct, plts, etc.
- **ROW 18** [P1]: The note mentions no specific cancer-related medications, but the extracted data incorrectly states 'empty'.
- **ROW 18** [P1]: The note does not mention any recent treatment changes, but the extracted data incorrectly states 'empty'.
- **ROW 18** [P1]: The goal of treatment is not clearly stated as palliative in the note, but the extracted data incorrectly states 'palliative'.
- **ROW 29** [P1]: Inaccurate statement. The patient already had a new diagnosis of metastatic adenocarcinoma of the pancreas at the previous visit, so it's not 'new' in this context.
- **ROW 31** [P1]: Missing gemcitabine, the only cancer-related medication.
- **ROW 31** [P1]: Unexplained medical jargon (elevated white blood cell count, low red blood cell count, low hemoglobin, low hematocrit, and high neutrophil absolute count).
- **ROW 31** [P1]: Unexplained medical jargon (Cancer Antigen 19-9).
- **ROW 32** [P1]: Incomplete sentence, missing the name of the chemotherapy combination.
- **ROW 33** [P1]: Incomplete sentence, missing critical information about the dosing schedule (days 1, 8, 15).
- **ROW 35** [P1]: Unexplained medical jargon (IGF-1).
- **ROW 36** [P1]: Incomplete sentence with missing critical information.
- **ROW 40** [P1]: Incomplete sentence with missing critical information (dose amount).
- **ROW 41** [P1]: Incorrect goal of treatment.
- **ROW 62** [P1]: Incomplete sentence with missing critical information.
- **ROW 72** [P1]: Contains complex medical jargon that is not explained and may be confusing to an 8th-grade reader.
- **ROW 77** [P1]: Incorrect goal of treatment. The patient is on surveillance after completing adjuvant therapy, so the goal should be 'surveillance' rather than 'curative'.
- **ROW 79** [P1]: The term 'adenocarcinoma' is not explained, which could be confusing for an 8th-grade reading level.
- **ROW 84** [P1]: This sentence contains medical jargon that may not be understandable to an 8th-grade reader.
- **ROW 84** [P1]: This sentence uses complex medical terminology and is not easily understandable.
- **ROW 84** [P1]: This sentence contains medical jargon that may not be understandable to an 8th-grade reader.
- **ROW 84** [P1]: This sentence contains medical jargon and is not easily understandable.
- **ROW 87** [P1]: Incomplete sentence, missing dosage information.
- **ROW 90** [P1]: Incomplete sentence with missing critical info.
- **ROW 90** [P1]: Incomplete sentence with missing critical info.
- **ROW 92** [P1]: Inaccurate information. The lab result mentions CA 19-9 = 207, but does not specify whether this is an increase or decrease from previous levels.

---

## ROW 1 — ⚠️ ISSUES

**Type**: Moderately differentiated pancreatic adenocarcinoma
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | Stage of cancer is left blank, though it can be reasonably inferred as potentially resectable based on the note. | potentially resectable pancreatic adenocarcinoma |
| P2 | Lab_Results.lab_summary | CA 19-9 value is incorrect (6,105 instead of 77,736 at baseline and 6,105 after treatment). | Baseline *****-9 markedly elevated at 77,736 (in the context of obstructive jaundice)...recently ima |
| P2 | Current_Medications.current_meds | Field is empty, but the note mentions ongoing chemotherapy treatment. | He is now s/p 4 cycles of neoadjuvant chemotherapy with [REDACTED] |

*Extraction summary*: Most fields are clean, but there are minor issues with the stage of cancer, lab results, and current medications.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 4 — ⚠️ ISSUES

**Type**: Metastatic pancreatic ductal adenocarcinoma
**Stage**: Stage IV (metastatic to liver and peritoneum)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine-based regimen mentioned as a potential future treatment, but not listed under current medications). | We talked about potential side fx and risks, esp in terms of infectious complications, and adverse i |
| P2 | Treatment_Changes | Supportive medications listed are not exclusively cancer-related supportive care. | Supportive medications listed include Fentanyl patch, Dilaudid, DexAMETHasone, ondansetron, which ar |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medication and non-exclusive listing of supportive medications.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 6 — ⚠️ ISSUES

**Type**: Pancreatic neuroendocrine tumor, grade 2, well-differentiated
**Stage**: Originally Stage IIB, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Current_Medications | The note mentions 'lanreotide', not 'capecitabine'. | continue lanreotide 120 mg/mo |
| P2 | Cancer_Diagnosis | The note does not specify the original stage as 'IIB'. | Primary pancreatic neuroendocrine tumor s/p [REDACTED] procedure in 2013. |

*Extraction summary*: Major error in current medications and minor issue in cancer diagnosis stage. Other fields are clean.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The extracted data states 'Continue lanreotide 120 mg/mo', but the letter incorrectly mentions 'capecitabine'. | You continue to take capecitabine. |
| P2 | The sentence uses 'cancer' instead of 'neuroendocrine tumor', which is less precise. | Imaging findings from October 5, 2015, show that the cancer in your liver and ly |

*Letter summary*: The letter contains a factual error regarding the medication and a minor precision issue.

---

## ROW 7 — ⚠️ ISSUES

**Type**: Well-differentiated pancreatic ductal adenocarcinoma
**Stage**: pT3 N1

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. The note mentions metformin, methylphenidate, ondansetron, and oxycodone, but only ondansetron and oxycodone are listed under supportive_meds. However, only cancer-related medications should be included in current_meds. | Medications the patient states to be taking prior to today's encounter. METFORMIN HCL (METFORMIN ORA |
| P2 | Treatment_Changes | Incomplete. The note mentions that the patient is currently receiving adjuvant chemotherapy with gemcitabine alone after discontinuing [REDACTED]-paclitaxel due to cumulative peripheral sensory neuropathy. The extraction does not mention the initial combination therapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |
| P2 | Treatment_Goals | Inaccurate. The goal is adjuvant therapy, not curative. The note mentions that the patient is receiving adjuvant chemotherapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |
| P2 | Response_Assessment | Inaccurate. The response assessment should include the patient's current condition and the absence of disease recurrence, not just the improvement in labs. | The patient's labs are noted to be significantly improved, allowing continuation of gemcitabine. The |
| P2 | Medication_Plan | Incomplete. The note mentions that the patient is currently receiving adjuvant chemotherapy with gemcitabine alone after discontinuing [REDACTED]-paclitaxel due to cumulative peripheral sensory neuropathy. The extraction does not mention the initial combination therapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |
| P2 | Therapy_plan | Incomplete. The note mentions that the patient is currently receiving adjuvant chemotherapy with gemcitabine alone after discontinuing [REDACTED]-paclitaxel due to cumulative peripheral sensory neuropathy. The extraction does not mention the initial combination therapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |

*Extraction summary*: Most fields are clean, but there are minor issues with completeness and accuracy in medication and treatment plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate staging information. The correct staging is pT3 N1, not Stage II-III. | You have a well-differentiated pancreatic ductal adenocarcinoma (cancer that sta |
| P2 | Unnecessary detail about the date of the CT scan. It can be simplified. | Recent CT scan on 10/21/2015 shows post-operative changes without evidence of re |
| P2 | Lacks context about why the treatment was changed. | You are currently receiving adjuvant chemotherapy with gemcitabine alone. |

*Letter summary*: The letter contains inaccuracies in staging information and overly detailed dates, which can be simplified for better readability.

---

## ROW 14 — ⚠️ ISSUES

**Type**: Grade 3 neuroendocrine tumor, with intermediate grade differentiation, of duoden
**Stage**: Originally localized, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. Only 'capecitabine' is listed, while 'temozolomide' is also a cancer-related medication. | She is now s/p 5 cycles of chemotherapy consisting of the combination of capecitabine/temozolomide. |

*Extraction summary*: One minor issue found in Current_Medications. All other fields are clean.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate description of the tumor location. The tumor is of duodenal origin, not pancreatic. | You came in for a follow-up visit regarding your neuroendocrine tumor of the pan |
| P2 | Minor readability issue. Could be more explicit about what 'stable' means. | MRI scans from early June showed that your disease is stable. |
| P2 | Could be more specific about what was checked during the physical exam. | During your physical exam, no new issues were found. |
| P2 | Minor readability issue. Could explain briefly what these medications do. | You will continue to take ondansetron and oxycodone to manage side effects. |
| P2 | Minor readability issue. Could specify the purpose of the CT scan more clearly. | After this cycle, you will have a CT scan to check on your tumor. |

*Letter summary*: The letter contains inaccuracies and minor readability issues that need addressing.

---

## ROW 15 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: Originally Stage IV, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | current_meds | The patient is taking turmeric, mushroom extract, and cannabis products, which are not included in the current_meds field. | He does take turmeric, mushroom extract and cannabis products |
| P2 | Treatment_Changes | The note mentions exploring clinical trial options, particularly cell therapy, which is not reflected in the Treatment_Changes field. | As he was very interested in clinical trials, we decided to explore this with the phase I group as w |
| P2 | Imaging_Plan | The note indicates a recent CT scan was performed, but the Imaging_Plan field only mentions future CT Chest without specifying the purpose or timing. | A recent CT scan done shows new peritoneal metastases. |

*Extraction summary*: Most fields are clean, but there are minor issues with missing complementary therapies, clinical trial exploration, and recent imaging details.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information (specific medication name). | We will resume a medication. You responded initially quite well to a medication  |

*Letter summary*: Letter has a critical issue with incomplete medication information.

---

## ROW 17 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreas
**Stage**: Stage IV (metastatic to peritoneum)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | The summary mentions 'returning for follow-up imaging and chemotherapy management,' but the note only specifies follow-up imaging. | She has now had 4 full cycles and returns today for follow-up imaging. |
| P2 | Treatment_Changes.recent_changes | The recent changes mention starting denosumab, but the note indicates it's part of the future plan, not a recent change. | We plan to start denosumab. |
| P2 | Imaging_Plan.imaging_plan | The imaging plan only mentions 'CT Chest,' but the note specifies both CT Chest and CT Abdomen/Pelvis. | CT Chest With Contrast and CT Abdomen/Pelvis With Contrast |

*Extraction summary*: Most fields are clean, but there are minor issues with the summary, recent treatment changes, and imaging plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 18 — ⚠️ ISSUES

**Type**: Pancreatic ductal adenocarcinoma, grade 2, with separate intra-ampullary papilla
**Stage**: Originally Stage IIB, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Cancer_Diagnosis.Stage_of_Cancer | The note states the patient originally had Stage IB pancreatic adenocarcinoma, and now has metastatic disease, but the extracted 'Stage IIB' is not supported. | Mr. ***** is a 67 y.o. male whom I am seeing as a video visit at the UCSF Comprehensive Cancer Cente |
| P1 | Lab_Results.lab_summary | The lab results provided in the extracted data do not match the note, which does not contain specific lab values like WBC, Hct, plts, etc. | The note does not provide specific lab values for WBC, Hct, plts, etc. |
| P1 | Current_Medications.current_meds | The note mentions no specific cancer-related medications, but the extracted data incorrectly states 'empty'. | The note does not mention any current cancer-related medications. |
| P1 | Treatment_Changes.recent_changes | The note does not mention any recent treatment changes, but the extracted data incorrectly states 'empty'. | The note does not mention any recent treatment changes. |
| P1 | Treatment_Goals.goals_of_treatment | The goal of treatment is not clearly stated as palliative in the note, but the extracted data incorrectly states 'palliative'. | The note discusses ongoing treatment and future options without explicitly stating the goal as palli |

*Extraction summary*: Major errors in staging, lab results, current medications, treatment changes, and treatment goals. Other fields are clean.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 21 — ⚠️ ISSUES

**Type**: Metastatic pancreatic cancer
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (5-FU/LV plus irinotecan). | On this basis, he initiated 2nd-line chemotherapy consisting of the combination of 5-*****/LV plus * |
| P2 | Treatment_Changes | Supportive medications missing (lidocaine-prilocaine, lorazepam, mirtazapine). | Medications the patient states to be taking prior to today's encounter. ... lidocaine-prilocaine (EM |
| P2 | Therapy_plan | Incorrectly states 'Continue/start: irinotecan'. Patient is no longer a candidate for further treatment. | He is no longer a candidate for any further salvage treatment in terms of either SOC therapies or pu |

*Extraction summary*: Most fields are clean, but there are minor issues regarding missing cancer-related medications and incorrect continuation of therapy plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 29 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | Inaccurate summary; mentions 'new diagnosis' instead of 'follow-up'. | This is an independent visit. |
| P2 | Current_Medications.current_meds | Incomplete; only lists Gemcitabine and Abraxane, but does not include other cancer-related medications like Zoledronic acid. | She elected to go on the ***** 301 trial. |
| P2 | Treatment_Changes.recent_changes | Inaccurate; mentions 'Restarted Gemcitabine + Abraxane', but the note indicates it was resumed after a break. | She was recommended to restart Gemcitabine + Abraxane. |
| P2 | Treatment_Goals.goals_of_treatment | Inaccurate; mentions 'palliative', but the note suggests a more aggressive approach with a focus on treatment response. | It is reassuring to see that she has improved clinically and that she has been able to tolerate trea |
| P2 | Medication_Plan.medication_plan | Incomplete; does not include all supportive medications mentioned in the note. | She takes Oxycodone ER 30 mg TID and Oxycodone IR 5 mg 3 - 4 tabs/day for breakthrough pain. |
| P2 | Lab_Plan.lab_plan | Inaccurate; mentions 'No labs planned', but the note suggests ongoing monitoring. | Key elements of latest CBC/diff values... Please see Chart Review for additional result details |

*Extraction summary*: Most fields are clean, but there are minor issues with the summary, medication listing, treatment goals, and lab plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate statement. The patient already had a new diagnosis of metastatic adenocarcinoma of the pancreas at the previous visit, so it's not 'new' in this context. | You have a new diagnosis of metastatic adenocarcinoma (cancer that started in gl |
| P2 | Slightly imprecise wording. The original note specifies the exact areas where the tumors decreased in size. | On CT scans, there was a significant decrease in the size of tumors in the pancr |
| P2 | Unexplained medical jargon. 'Liver spots' is not clear enough. | However, some liver spots have stayed the same size. |

*Letter summary*: The letter contains inaccuracies and minor readability issues that need addressing.

---

## ROW 31 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreas
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Current_Medications | Missing gemcitabine, the only cancer-related medication. | We initially saw him two months ago. Because of his comorbidities and poor performance status, we re |

*Extraction summary*: Major error in Current_Medications due to missing gemcitabine.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Unexplained medical jargon (elevated white blood cell count, low red blood cell count, low hemoglobin, low hematocrit, and high neutrophil absolute count). | Your lab results show elevated white blood cell count, low red blood cell count, |
| P1 | Unexplained medical jargon (Cancer Antigen 19-9). | Additionally, your Cancer Antigen 19-9 level is significantly elevated. |

*Letter summary*: The letter contains unexplained medical jargon that could confuse the patient.

---

## ROW 32 — ⚠️ ISSUES

**Type**: Metastatic moderately differentiated adenocarcinoma of pancreatic or biliary ori
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine) mentioned in the note. | There are several possible chemotherapy options for metastatic pancreatic cancer, with the choice of |
| P2 | Treatment_Changes | Supportive medications listed are not exclusively cancer-treatment-related. | Supportive medications include primary prophylaxis with growth factor support ([REDACTED] or Neupoge |
| P2 | Treatment_Goals | Goals of treatment are stated as 'palliative', but the note suggests a more nuanced approach including disease control and extending survival. | The mainstay of treatment at this point should consist of systemic therapy, that the goals of such t |
| P2 | Radiotherapy_plan | Plan is vague and lacks specific details. | For now, I will see how this responds to systemic therapy, but we could consider spot RT to that are |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing cancer-related medications, classification of supportive medications, and specificity of radiotherapy plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence, missing the name of the chemotherapy combination. | You are inclined to move ahead with standard of care (SOC) chemotherapy with a c |
| P2 | Unexplained medical jargon ('grade _ neutropenia') and incomplete sentence. | Supportive medications include primary prophylaxis with growth factor support (a |

*Letter summary*: The letter contains minor issues that need addressing for clarity and completeness.

---

## ROW 33 — ⚠️ ISSUES

**Type**: Metastatic pancreatic adenocarcinoma with biopsy-proven liver metastasis
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Lab_Results | The lab results include values not mentioned in the note. | The note does not provide specific lab values such as Alkaline Phosphatase, Bilirubin, Alanine trans |
| P2 | Current_Medications | The field is empty, but the note mentions several cancer-related medications. | The note mentions '*****' (likely a chemotherapy regimen) and 'irinotecan'. |
| P2 | Treatment_Changes | The field incorrectly states 'Switch to gemcitabine combined with nab-paclitaxel', which is part of the future plan, not a past change. | The note states 'my recommendation is to switch her therapy to gemcitabine combined with *****-pacli |
| P2 | Therapy_plan | The field incorrectly states 'Continue irinotecan', which is not part of the future plan. | The note recommends switching to gemcitabine combined with nab-paclitaxel. |

*Extraction summary*: Most fields are clean, but there are minor issues with lab results, current medications, treatment changes, and therapy plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence, missing critical information about the dosing schedule (days 1, 8, 15). | You will receive gemcitabine and nab-paclitaxel every 28 days. |
| P2 | Minor readability issue, could be more clear. | A CT scan of your chest, abdomen, and pelvis will be done after two months of tr |

*Letter summary*: Letter contains an incomplete sentence with missing critical information and a minor readability issue.

---

## ROW 35 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreatic tail
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | The field is empty, but the note mentions that the patient is on several medications, though none are cancer-related. | Current Outpatient Prescriptions: ERGOCALCIFEROL, VITAMIN D2, (VITAMIN D ORAL), escitalopram oxalate |
| P2 | Treatment_Changes | The field is empty, but the note discusses potential future treatment changes based on the results of the biopsy and lab tests. | If pathologic confirmation of metastatic disease is obtained, the patient will be considered for one |
| P2 | Lab_Plan | The field is incomplete. It should include CA 19-9 levels in addition to CBC with diff and LFTs. | We will monitor treatment response with monthly CA 19-9 levels and restaging CT scans every 2 months |

*Extraction summary*: Most fields are clean, but there are minor issues with missing non-cancer medications, potential future treatment changes, and incomplete lab plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Unexplained medical jargon (IGF-1). | Depending on your IGF-1 levels, you may be eligible for clinical trials involvin |
| P2 | Explanation of adenocarcinoma is too detailed for 8th-grade reading level. | You have a type of cancer called adenocarcinoma (cancer that started in gland ce |

*Letter summary*: The letter contains minor readability issues and unexplained medical jargon.

---

## ROW 36 — ⚠️ ISSUES

**Type**: Nonfunctioning pancreatic neuroendocrine tumor
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. Everolimus is listed, but the note mentions multiple doses (2.5 mg and 10 mg). | everolimus (AFINITOR) 2.5 mg TAB 7.5 mg (3 tabs) daily  90 tablet  6    everolimus 10 mg TAB Take 1 |
| P2 | Treatment_Changes | Incomplete. The note mentions holding everolimus during partial SBO, but this detail is not fully captured. | Everolimus held during that period of time, resumed two weeks ago. |
| P2 | Treatment_Goals | Slightly imprecise. 'Palliative' is correct, but 'durable disease control' is also mentioned in the note. | with evidence of good durable disease control and reasonably good (in fact, improved) tolerance on c |
| P2 | Medication_Plan | Slightly imprecise. The note mentions starting non-insulin pharmacologic treatment in the future, but this is not clearly stated. | discussed potential plan to start non-insulin pharmacologic rx in the future. |

*Extraction summary*: Most fields are clean, but there are minor issues related to completeness and precision in medication details and treatment goals.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information. | Some liver tumors have grown slightly, while others have shrunk. |

*Letter summary*: Letter contains an incomplete sentence that needs clarification.

---

## ROW 40 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications (gemcitabine and Abraxane) in the medication plan. | We recommend a course of treatment with gemcitabine and Abraxane. |

*Extraction summary*: One minor issue identified regarding the inclusion of cancer-related medications in the medication plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information (dose amount). | We plan to increase the dose of your fentanyl and added Reglan and when necessar |

*Letter summary*: Letter contains an incomplete sentence with missing critical information.

---

## ROW 41 — ⚠️ ISSUES

**Type**: Invasive adenocarcinoma, well- to moderately differentiated, with perineural inv
**Stage**: Originally Stage IIB (node-positive), now with concern for locoregional recurren

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications. | He is continuing with an insulin regimen and regular use of enzyme supplements with meals. |
| P2 | Treatment_Changes | Missing recent treatment changes. | The patient received 12 cycles of neoadjuvant chemotherapy with essentially stable disease. |
| P1 | Treatment_Goals | Incorrect goal of treatment. | The patient is now approximately 18 months post-total pancreatectomy, and the purpose of this visit  |
| P2 | Imaging_Plan | Missing recommended imaging. | Further evaluation with PET/CT may be helpful for confirmation. |

*Extraction summary*: Several fields contain minor omissions and one major classification error. Overall, the majority of fields are accurate.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 43 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Borderline resectable pancreatic adenocarcinoma due to <180 degrees of vascular 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications. | The note mentions 'Continue to monitor [REDACTED] July 04 [REDACTED] 4 weeks.' and 'Continue [REDACT |

*Extraction summary*: Most fields are clean, but the current medications related to cancer treatment are missing.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 59 — ⚠️ ISSUES

**Type**: Well to moderately differentiated adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The field is empty, but the note provides enough information to infer a stage. | Pathology showed a 2.5 cm well to moderately differentiated adenocarcinoma with a positive retroperi |
| P2 | Cancer_Diagnosis.Type_of_Cancer | The type of cancer is described as 'Well to moderately differentiated adenocarcinoma of the pancreas', but the note specifies 'pylorus sparing gastrectomy' which might imply a different location. | Pathology showed a 2.5 cm well to moderately differentiated adenocarcinoma with a positive retroperi |
| P2 | Current_Medications.current_meds | The field is empty, but the note mentions 'metFORMIN' which is related to hyperglycemia consistent with type 2 diabetes, though not directly cancer-related. | METFORMIN 500 mg 24 hour extended release tablet Take 500 mg by mouth daily with dinner |
| P2 | Treatment_Changes.recent_changes | The field is empty, but the note indicates ongoing surveillance and no recent changes in treatment. | She will continue on surveillance. We'll see her again in 6 months. |
| P2 | Imaging_Plan.imaging_plan | The field only mentions 'CT Chest', but the note suggests ongoing surveillance which likely includes both CT Chest and CT Abdomen/Pelvis. | Comprehensive metabolic panel and complete blood count results are provided, and imaging reports for |

*Extraction summary*: Most fields are clean, but there are minor issues with missing inferred cancer stage, potential misclassification of cancer type, and incomplete imaging plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 62 — ⚠️ ISSUES

**Type**: Pancreatic ductal adenocarcinoma, moderately differentiated
**Stage**: Originally Stage IIB, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The note does not specify the original stage of the cancer, only that it is now metastatic (Stage IV). The extraction invents the original stage as 'IIB'. | The note mentions 'resected pancreaticobiliary cancer' and 'metastatic disease to the liver', but do |
| P2 | Treatment_Changes.recent_changes | The note states 'Started [REDACTED] [REDACTED] 11/05/20', but the exact medication is redacted. The extraction should reflect this uncertainty. | The note says 'Started [REDACTED] [REDACTED] 11/05/20'. |
| P2 | follow_up_next_visit.Next clinic visit | The note does not specify the next clinic visit date, but it implies future visits are planned. The extraction should reflect this implication. | The note does not explicitly state the next clinic visit date. |

*Extraction summary*: Most fields are clean, but there are minor issues with the inferred original cancer stage, the redacted medication start date, and the lack of a specified next clinic visit date.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information. | You started a new medication on 11/05/20. |

*Letter summary*: Letter contains an incomplete sentence with missing critical information.

---

## ROW 72 — ⚠️ ISSUES

**Type**: Moderately differentiated adenocarcinoma
**Stage**: Originally borderline resectable, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The stage description 'Originally borderline resectable, now metastatic (Stage IV)' is slightly imprecise. The note mentions the initial stage as 'borderline resectable' but does not explicitly state the current stage as 'Stage IV'. | He presented in December 2014. CT scan, performed at ***** for abdominal and back pain, demonstrated |
| P2 | Treatment_Changes.recent_changes | The recent treatment changes mention switching to a reduced dose of a [REDACTED] drug, but the exact name is not provided. This could be more precise. | We then elected to resume chemotherapy but switched to reduced dose [REDACTED]. After 8 cycles, he h |

*Extraction summary*: Most fields are clean, but there are minor issues with the stage description and the lack of specificity regarding the [REDACTED] drug.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Contains complex medical jargon that is not explained and may be confusing to an 8th-grade reader. | Your cancer is currently showing stable disease in the abdomen but progressing p |
| P2 | The sentence is long and contains several complex terms that may be difficult to understand. | We decided to resume chemotherapy but switched to a reduced dose. After 8 cycles |

*Letter summary*: The letter contains some complex medical jargon that may be confusing to an 8th-grade reader and requires simplification.

---

## ROW 77 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the tail of the pancreas
**Stage**: Resectable at diagnosis, now with negative margins and lymph nodes

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | Inaccurate summary of the visit reason. It mentions 'follow-up visit for adjuvant therapy with gemcitabine and capecitabine and surveillance,' but the patient has already completed 6 cycles of adjuvant therapy. | He has had 6 cycles and is on surveillance. |
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The stage description is imprecise. The note does not provide a specific stage, only that it was resectable at diagnosis. | Because of renal and splenic invasion, the left kidney and left adrenal and spleen were included in  |
| P1 | Treatment_Goals.goals_of_treatment | Incorrect goal of treatment. The patient is on surveillance after completing adjuvant therapy, so the goal should be 'surveillance' rather than 'curative'. | He has had 6 cycles and is on surveillance. |
| P2 | follow_up_next_visit.Next clinic visit | The next visit is described as 'surveillance for pancreatic cancer', which is accurate, but it lacks detail about the timing or frequency of the next visit. | Re his pancreatic cancer, he will continue on surveillance. |

*Extraction summary*: Most fields are clean, but there are issues with the visit summary, cancer stage description, treatment goals, and the next visit details.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Unexplained medical jargon 'recurrent or metastatic disease'. | Recent imaging shows no evidence of recurrent or metastatic disease in the abdom |
| P2 | Unexplained medical jargon 'transaminitis'. | Your liver enzymes (AST and ALT) are elevated, indicating transaminitis. |

*Letter summary*: Letter is mostly clean but contains some unexplained medical jargon that could be simplified further.

---

## ROW 79 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma with metastatic disease to liver
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | The field is empty, but the note mentions no cancer-related medications. | Medications the patient states to be taking prior to today's encounter. |
| P2 | Treatment_Goals | The field states 'palliative', but the note suggests a goal of achieving a deep and durable remission, which aligns more closely with 'curative intent'. | the mainstay of treatment at this juncture should consist of systemic therapy with the goal of achie |
| P2 | follow_up_next_visit | The field states 'No explicit timing or mention of next clinic visit in the document.' However, the note implies a follow-up within the next week for starting treatment. | starting treatment in the next week or so |

*Extraction summary*: Most fields are clean, but there are minor issues with the classification of treatment goals, the completeness of current medications, and the clarity of follow-up timing.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The term 'adenocarcinoma' is not explained, which could be confusing for an 8th-grade reading level. | You have been diagnosed with pancreatic adenocarcinoma (cancer that started in g |
| P2 | While 'CA 19-9' is mentioned, it is not fully explained in simple terms. | Tests show that your CA 19-9 (a tumor marker) level is high at 852. |
| P2 | The term 'complex cystic and solid mass' is somewhat technical and could be simplified. | Imaging and biopsy confirm a complex cystic and solid mass in the tail of your p |

*Letter summary*: The letter contains minor issues with medical jargon that could confuse an 8th-grade reader. Some terms need further simplification.

---

## ROW 82 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Stage IV (metastatic to liver and lung)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing current cancer-related medication (fentanyl patch). | fentaNYL (DURAGESIC) 25 mcg/hr patch Place 1 patch onto the skin every other day. For cancer pain. |

*Extraction summary*: One minor issue found in Current_Medications.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 84 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Originally Stage IIB, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The note does not specify the original stage of the cancer as 'Stage IIB'. It only mentions the current stage as 'metastatic (Stage IV)' | Mr. ***** is a 59 y.o. male who returns to our GI Oncology practice at the UCSF Comprehensive Cancer |
| P2 | Current_Medications.current_meds | The note mentions 'atezolizumab' and 'cobimetinib', but only 'atezolizumab' is listed. | consisting of the combination of atezolizumab, a PD-L1 inhibitor (administered on a q2 weekly schedu |
| P2 | Treatment_Changes.recent_changes | The note mentions switching to 'atezolizumab' and 'cobimetinib', but the extraction only lists 'atezolizumab'. | consisting of the combination of atezolizumab, a PD-L1 inhibitor (administered on a q2 weekly schedu |
| P2 | Medication_Plan.medication_plan | The note mentions 'atezolizumab' and 'cobimetinib', but the extraction only lists 'atezolizumab'. | consisting of the combination of atezolizumab, a PD-L1 inhibitor (administered on a q2 weekly schedu |
| P2 | Therapy_plan.therapy_plan | The note mentions 'atezolizumab' and 'cobimetinib', but the extraction only lists 'atezolizumab'. | consisting of the combination of atezolizumab, a PD-L1 inhibitor (administered on a q2 weekly schedu |

*Extraction summary*: Most fields are clean, but there are minor issues regarding the completeness of medication listings and the inferred original stage of the cancer.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | This sentence contains medical jargon that may not be understandable to an 8th-grade reader. | The cancer is currently showing stable to slightly enlarging sites of measurable |
| P1 | This sentence uses complex medical terminology and is not easily understandable. | Additionally, stable disease in the post-pancreatectomy procedure surgical bed a |
| P1 | This sentence contains medical jargon that may not be understandable to an 8th-grade reader. | You switched to the combination of atezolizumab (a PD-L1 inhibitor) and cobimeti |
| P1 | This sentence contains medical jargon and is not easily understandable. | You are continuing on the crossover arm of the trial, consisting of atezolizumab |

*Letter summary*: The letter contains several sentences with medical jargon that may not be understandable to an 8th-grade reader. These need to be simplified for better readability.

---

## ROW 87 — ⚠️ ISSUES

**Type**: Pancreatic neuroendocrine tumor, well-differentiated, glucagon producing, with m
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing octreotide, which is a cancer-related medication. | octreotide (SANDOSTATIN *****) 30 mg every 30 (thirty) days. |
| P2 | Treatment_Changes | Missing mention of increased metformin dosage. | Recent metformin and exercise for higher sugars- now fine. |
| P2 | Treatment_Goals | Should be 'palliative' but could be more specific given the context. | Tolerating Everolimus well--continue with Everolimus 10 mg daily |
| P2 | Response_Assessment | Could be more precise about the nature of the progression. | My interpretation is that there is slow PD v December 2016 |
| P2 | Medication_Plan | Missing mention of increased metformin dosage. | Recent metformin and exercise for higher sugars- now fine. |
| P2 | Procedure_Plan | Mentions liver directed therapy but does not specify it as a future consideration. |  |
| P2 | Imaging_Plan | Does not specify the exact timing for the next MRI. | Review at [REDACTED] dotatate MRI |
| P2 | Lab_Plan | Does not specify the exact timing for the next lab tests. | Check lipids, hgb A1C q 3 mo. Monthly chem panel-- WITH phosphorus. |

*Extraction summary*: Most fields are clean, but there are minor issues regarding completeness and specificity in several fields.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence, missing dosage information. | You will continue taking Everolimus . |
| P2 | Unexplained medical term 'hemoglobin A1c'. | Your hemoglobin A1c is high at 7.7, indicating higher blood sugar levels. |
| P2 | Unexplained medical term 'physical exam'. | You have multiple small bruises noted on physical exam. |
| P2 | Unexplained medical term 'triglycerides'. | You will continue monitoring your triglycerides quarterly. |

*Letter summary*: The letter has some issues with incomplete sentences and unexplained medical terms.

---

## ROW 90 — ⚠️ ISSUES

**Type**: 
**Stage**: Originally Stage IIB, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Type_of_Cancer | Missing specific types of cancer (BRAF mutant melanoma and pancreatic neuroendocrine tumor). | Subjective ***** ***** is a 66 y.o. female who presents for f/u of *****her history of ***** mutant  |
| P2 | Current_Medications.current_meds | Missing current cancer-related medications (dabrafenib and trametinib). | continues on clinical trial, taking intermittent dabrafenib +***** ***** then trametinib alone ***** |
| P2 | Treatment_Changes.recent_changes | Missing recent changes in dabrafenib and trametinib dosing. | continues to tolerate intermittent dosing; will continue on this regimen of D+T for 2 weeks, then T  |
| P2 | Treatment_Goals.goals_of_treatment | Goals of treatment should include both palliative and symptom management. | Given documented ***** to liver-- favor trial of somatostatic analog (based on clarinet data showing |
| P2 | Imaging_Plan.imaging_plan | Missing regular PETCT per clinical trial. | Metastatic melanoma: --Cont to obtain routine PETCT per clinical trial |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing specific cancer types, current medications, treatment goals, and imaging plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical info. | Your glucose level is high at /dL, which is higher than normal. |
| P1 | Incomplete sentence with missing critical info. | Your dose of octreotide was reduced to for four days, then increased to for anot |

*Letter summary*: Letter contains incomplete sentences with missing critical information.

---

## ROW 91 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreas, moderately differentiated
**Stage**: Originally resectable, now with possible local recurrence

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The stage 'Originally resectable, now with possible local recurrence' is slightly imprecise. The note suggests uncertainty about recurrence. | He may well have local recurrence but with the current coronavirus crisis, it will be difficult to w |
| P2 | Treatment_Changes.recent_changes | The field is empty, but the note mentions a delay in starting treatment due to stent issues and hypertension. | He experienced a delay in starting treatment because of tumor ingrowth into his stent which required |
| P2 | Treatment_Changes.supportive_meds | The field is empty, but the note mentions controlling hypertension and creatinine levels. | These problems eventually were controlled and he has completed 6 cycles of therapy. |

*Extraction summary*: Most fields are clean, but there are minor issues with the staging precision, and omissions regarding recent treatment changes and supportive medications.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 92 — ⚠️ ISSUES

**Type**: Moderately differentiated adenocarcinoma
**Stage**: Originally borderline resectable, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine and nab-paclitaxel). | She has since opted to resume chemotherapy with gemcitabine/*****-paclitaxel, well-tolerated to date |
| P2 | Treatment_Changes | Missing recent treatment changes (resumed chemotherapy with gemcitabine and nab-paclitaxel). | She has since opted to resume chemotherapy with gemcitabine/*****-paclitaxel, well-tolerated to date |
| P2 | Response_Assessment | Inaccurate description of stable disease. The note mentions a suspicious lesion. | Nodular soft tissue along the right lower lobe suture line (3.1 x 2.8 cm) with SUV of 3.2, unchanged |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications and recent treatment changes, and an inaccurate description of stable disease.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate information. The lab result mentions CA 19-9 = 207, but does not specify whether this is an increase or decrease from previous levels. | Your CA 19-9 (a tumor marker) level has slightly increased to 207. |
| P2 | Complex medical jargon that might be confusing for an 8th-grade reading level. | Future considerations include incorporating a chemotherapy holiday at some point |

*Letter summary*: There are issues with accuracy and readability that need addressing.

---

## ROW 98 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine and Abraxane). | We initially saw her about 2 months ago. We recommended therapy with gemcitabine and Abraxane. |
| P2 | Treatment_Changes | Supportive medications listed are incomplete. Missing LORazepam (ATIVAN) and predniSONE (DELTASONE). | LORazepam (ATIVAN) 1 mg tablet... predniSONE (DELTASONE) 20 mg tablet... |
| P2 | Lab_Plan | Incorrect classification. Should be under 'Therapy_plan'. | Once we can get her albumin up to 2 or better, we can resume her chemotherapy. |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications and misclassified lab plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

